Which has stronger earnings & valuation, IQV or ICLR?

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.12 $1.36B $8.07 25.70 Icon $8.25B 1.54 $229.34M $5.62 29.56

Is IQV or ICLR more profitable?

IQVIA has a net margin of 8.33% compared to Icon's net margin of 5.35%. IQVIA's return on equity of 30.50% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Icon 5.35% 8.73% 4.96%

Does the media prefer IQV or ICLR?

In the previous week, IQVIA had 7 more articles in the media than Icon. MarketBeat recorded 14 mentions for IQVIA and 7 mentions for Icon. IQVIA's average media sentiment score of 1.10 beat Icon's score of 0.49 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Icon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.12 $1.36B $8.07 25.70 Medpace $2.53B 5.98 $451.12M $15.91 33.32

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Medpace 17.19% 120.89% 24.79%

Does the media refer more to IQV or MEDP?

In the previous week, IQVIA had 1 more articles in the media than Medpace. MarketBeat recorded 14 mentions for IQVIA and 13 mentions for Medpace. IQVIA's average media sentiment score of 1.10 beat Medpace's score of 0.77 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TECH or IQV?

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.16 $73.40M $0.69 103.42 IQVIA $16.31B 2.12 $1.36B $8.07 25.70

Is TECH or IQV more profitable?

Bio-Techne has a net margin of 9.05% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Bio-Techne's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 9.05% 13.57% 10.66% IQVIA 8.33% 30.50% 6.53%

Does the media favor TECH or IQV?

In the previous week, IQVIA had 7 more articles in the media than Bio-Techne. MarketBeat recorded 14 mentions for IQVIA and 7 mentions for Bio-Techne. IQVIA's average media sentiment score of 1.10 beat Bio-Techne's score of 0.53 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor A or IQV?

In the previous week, IQVIA had 1 more articles in the media than Agilent Technologies. MarketBeat recorded 14 mentions for IQVIA and 13 mentions for Agilent Technologies. IQVIA's average media sentiment score of 1.10 beat Agilent Technologies' score of 0.90 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IQVIA (IQV) Competitors

$207.39 -0.46 (-0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$205.44 -1.95 (-0.94%)

As of 08:00 PM Eastern

Compare

IQV vs. ICLR, MEDP, TECH, A, and CRL

Should you buy IQVIA stock or one of its competitors? MarketBeat compares IQVIA with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IQVIA include Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), Agilent Technologies (A), and Charles River Laboratories International (CRL). These companies are all part of the "medical" sector.

How does IQVIA compare to Icon?

IQVIA (NYSE:IQV) and Icon (NASDAQ:ICLR) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, IQVIA had 7 more articles in the media than Icon. MarketBeat recorded 14 mentions for IQVIA and 7 mentions for Icon. IQVIA's average media sentiment score of 1.10 beat Icon's score of 0.49 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

IQVIA currently has a consensus target price of $225.71, suggesting a potential upside of 8.83%. Icon has a consensus target price of $173.19, suggesting a potential upside of 4.27%. Given IQVIA's stronger consensus rating and higher probable upside, equities research analysts plainly believe IQVIA is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Icon	3 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.33

IQVIA has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Icon has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.12	$1.36B	$8.07	25.70
Icon	$8.25B	1.54	$229.34M	$5.62	29.56

IQVIA has a net margin of 8.33% compared to Icon's net margin of 5.35%. IQVIA's return on equity of 30.50% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Icon	5.35%	8.73%	4.96%

Summary

IQVIA beats Icon on 12 of the 16 factors compared between the two stocks.

How does IQVIA compare to Medpace?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IQVIA has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Medpace	17.19%	120.89%	24.79%

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.12	$1.36B	$8.07	25.70
Medpace	$2.53B	5.98	$451.12M	$15.91	33.32

IQVIA presently has a consensus price target of $225.71, indicating a potential upside of 8.83%. Medpace has a consensus price target of $469.50, indicating a potential downside of 11.45%. Given IQVIA's stronger consensus rating and higher possible upside, equities analysts plainly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07

In the previous week, IQVIA had 1 more articles in the media than Medpace. MarketBeat recorded 14 mentions for IQVIA and 13 mentions for Medpace. IQVIA's average media sentiment score of 1.10 beat Medpace's score of 0.77 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Medpace on 9 of the 16 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.16	$73.40M	$0.69	103.42
IQVIA	$16.31B	2.12	$1.36B	$8.07	25.70

Bio-Techne has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Bio-Techne presently has a consensus target price of $68.08, suggesting a potential downside of 4.60%. IQVIA has a consensus target price of $225.71, suggesting a potential upside of 8.83%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Bio-Techne has a net margin of 9.05% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
IQVIA	8.33%	30.50%	6.53%

In the previous week, IQVIA had 7 more articles in the media than Bio-Techne. MarketBeat recorded 14 mentions for IQVIA and 7 mentions for Bio-Techne. IQVIA's average media sentiment score of 1.10 beat Bio-Techne's score of 0.53 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

IQVIA beats Bio-Techne on 10 of the 16 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Agilent Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Agilent Technologies presently has a consensus price target of $159.35, suggesting a potential upside of 18.92%. IQVIA has a consensus price target of $225.71, suggesting a potential upside of 8.83%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Agilent Technologies is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

IQVIA has higher revenue and earnings than Agilent Technologies. IQVIA is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.45	$1.30B	$4.98	26.91
IQVIA	$16.31B	2.12	$1.36B	$8.07	25.70

Agilent Technologies has a net margin of 19.55% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
IQVIA	8.33%	30.50%	6.53%

89.6% of IQVIA shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IQVIA had 1 more articles in the media than Agilent Technologies. MarketBeat recorded 14 mentions for IQVIA and 13 mentions for Agilent Technologies. IQVIA's average media sentiment score of 1.10 beat Agilent Technologies' score of 0.90 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Agilent Technologies on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Charles River Laboratories International?

IQVIA (NYSE:IQV) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.12	$1.36B	$8.07	25.70
Charles River Laboratories International	$4.02B	2.76	-$144.34M	-$3.76	N/A

IQVIA has a net margin of 8.33% compared to Charles River Laboratories International's net margin of -4.59%. IQVIA's return on equity of 30.50% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Charles River Laboratories International	-4.59%	15.36%	6.61%

IQVIA has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, IQVIA had 7 more articles in the media than Charles River Laboratories International. MarketBeat recorded 14 mentions for IQVIA and 7 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.13 beat IQVIA's score of 1.10 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA currently has a consensus target price of $225.71, indicating a potential upside of 8.83%. Charles River Laboratories International has a consensus target price of $220.75, indicating a potential downside of 4.01%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

IQVIA beats Charles River Laboratories International on 11 of the 16 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IQV vs. The Competition

Export

Metric	IQVIA	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$34.69B	$7.63B	$7.05B	$23.46B
Dividend Yield	N/A	1.32%	2.68%	4.02%
P/E Ratio	25.70	50.28	27.15	31.08
Price / Sales	2.12	76.45	587.92	19.77
Price / Cash	11.63	26.85	29.22	18.64
Price / Book	5.33	7.32	10.75	4.77
Net Income	$1.36B	$162.30M	$3.58B	$1.06B
7 Day Performance	0.64%	-2.02%	-2.10%	-0.56%
1 Month Performance	14.52%	0.19%	3.32%	-0.11%
1 Year Performance	27.44%	4.13%	28.17%	16.64%

IQVIA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IQV IQVIA	4.1849 of 5 stars	$207.39 -0.2%	$225.71 +8.8%	+27.9%	$34.69B	$16.31B	25.70	93,000	Positive News Analyst Forecast
ICLR Icon	3.0451 of 5 stars	$170.94 -1.2%	$173.19 +1.3%	+11.4%	$13.25B	$8.25B	30.42	40,100
MEDP Medpace	1.9728 of 5 stars	$565.09 +1.3%	$467.08 -17.3%	+66.4%	$15.92B	$2.53B	35.52	6,200	News Coverage Analyst Forecast
TECH Bio-Techne	2.1711 of 5 stars	$70.92 +0.1%	$67.79 -4.4%	+31.7%	$11.09B	$1.22B	102.78	3,100
A Agilent Technologies	4.9234 of 5 stars	$130.78 +0.1%	$160.88 +23.0%	+9.1%	$36.91B	$6.95B	26.26	18,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:IQV) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Competitors